总部位于浙江湖州的万邦德，聚焦医药制造和医疗器械大健康产业，主营业务集医药制造和医疗器械研 发、生产、销售于一体。截至今年上半年，万邦德在医药制造板块拥有专利67个，其中发明专利50个， 实用新型专利14个，外观专利3个；公司主要产品之一石杉碱甲已分别获得美国专利、欧洲专利、日本 专利各1个。2025年上半年新增7个专利。 公司表示，下一步，将继续推动多肽新药的临床前药理学和毒理学研究，争取早日将新药推向临床阶 段，在已授权的专利加持下，快速将差异化的好药带给拥有相关治疗需求的患者群体。 半年报显示，经过多年积累，万邦德已构建完善的研发体系，拥有一支具备较高专业技术水平和较强自 主创新能力的研发团队，实现从仿制药向创新药的战略转型。重点推进中药、化学药、原料药的研发， 在研产品石杉碱甲、多肽新药、甲钴胺等在重大神经系统疾病、肥胖等代谢类疾病、自体免疫疾病、罕 见病等领域实现零的突破。 中证报中证网讯(王珞)9月25日，万邦德（002082）官微显示，公司自主研发的创新小分子环肽药物 (MCR环肽)，在针对DB/DB肥胖小鼠模型的临床前研究中，展现出优于现有明星药物GLP-1多肽的减重 效果；结合其对肌肉的保持 ...

Financial Performance - In 2024, the company achieved operating revenue of 1.443 billion, a year-on-year decrease of 6.39% [3] - Net profit attributable to shareholders increased by 12.66% to 55.441 million [3] - The pharmaceutical sector's price adjustments in response to national policies have begun to mitigate the impact of collective procurement [3] Business Segments - The medical device segment has expanded its market presence, covering 80% of provinces and over 50 cities [4] - The South African subsidiary has shown significant growth, leveraging local distribution networks to introduce domestic medical equipment to the African market [4] Research and Development - The company is focusing on innovative drugs, generic drugs, raw materials, and traditional Chinese medicine, with a dedicated R&D team of 120 [6] - Key projects include clinical trials for drugs targeting Alzheimer's and other serious conditions, with FDA approvals for several products [6] Investor Relations - The company emphasizes transparency and interaction in investor relations, utilizing various communication channels to ensure effective information dissemination [7] - Future plans include enhancing digital capabilities and conducting scenario-based roadshows to strengthen investor understanding of the company's growth logic [7]